PD-L1 IHC 28-8 pharmDx
Agilent Technologies, Inc. · Decision date Sep 11, 2026
What did the FDA decide?
The FDA recorded decision OK30 on 2026-09-11 for P150025/S020, a 30-Day Notice supplement to the PMA for PD-L1 IHC 28-8 pharmDx, submitted by Agilent Technologies, Inc. The listed specialty is Pathology. The recorded supplement reason is a process change affecting manufacturer, sterilizer, packager or supplier arrangements.
The recorded statement covers approval of manufacturing process and equipment changes for filling and capping. This is a supplement-level action tied to the existing PMA, not a new approval of the device as a whole. The source does not identify the specific filling or capping equipment, the manufacturing site, or any validation data, and it gives no clinical, analytical performance or labeling information. Whether the change affects device performance or current labeling cannot be determined from this record.
FDA approval order statement
approval of manufacturing process and equipment changes for filling and capping
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Pathology
- Decision date
- Sep 11, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P150025/S020
- Regulatory pathway
- PMA supplement
- Applicant
- Agilent Technologies, Inc.
- Product code
- Not reported
- Decision code
- OK30
- Decision date
- Sep 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
- Applicant
- Agilent Technologies, Inc.
- Product code
- Not reported
For the original device and its historical approval scope, see PMA P150025. Subsequent supplements may change the device or its indications.
FDA decision timeline
P150025 · Original PMA
PD-L1 IHC 28-8 pharmDx
P150025/S018 · Related supplement
PD-L1 IHC 28-8 pharmDx
P150025/S020 received
Application receipt date recorded by FDA.
P150025/S020 · FDA decision
30-Day Notice
P150025/S019 · Related supplement
PD-L1 IHC 28-8 pharmDx
Timeline entries are records held by MedtechLedger for P150025. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150025
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PD-L1 IHC 28-8 pharmDxP150025 | Agilent Technologies, Inc. | PMA approval | Oct 9, 2015 | FDA |
PD-L1 IHC 28-8 pharmDxP150025/S018 | Agilent Technologies, Inc. | PMA supplement | Jul 1, 2026 | FDA |
PD-L1 IHC 28-8 pharmDxP150025/S019 | Agilent Technologies, Inc. | PMA supplement | Sep 21, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Agilent Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5301 Stevens Creek Blvd., Santa Clara, CA, 95051
Sources and methodology
- Original FDA record: P150025/S020
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

